New virus is capable of attacking 99% of HIV strains
According to the International Aids Society this is an exciting breakthrough. Human trials will begin in 2018 to see if it is possible to prevent or treat infections. According to Linda-Gail Bekker, the group's president, these antibodies seem to go beyond the natural and may have applications than anticipated.
How the antibody works
Researchers explain that in our body we have antibodies that fight to combat HIV. Unfortunately, this virus has a great ability to modify itself, making it difficult for the immune system to function.
However, some patients are able to develop broad, attacking neutralizing antibodies capable of killing extensions of HIV strains. The scientists' creation combines three broadly neutralizing types of antibodies as a way to treat HIV, or prevent infection. They are more powerful and more efficient than the ones we have in our body.
So far, the experiment was done with 24 monkeys and experts realized that they had an impressive degree of protection.
Vista as a solution for the elderly , morbidly obese or people suffering from health problems and reduced mobility, a pill has been created that transforms the way the body consumes energy. With this, it would be possible to increase the fat burning of these people and make them enjoy the benefits of physical activities a little.
The unpublished product in the country is an anticoagulant, with the trade name Lixiana (edoxabana). The drug is produced by the Japanese company Daiichi Sankyio Brasil Farmacêutica Ltda. According to Anvisa, the drug has two specific therapeutic indications: Reduced risk of stroke or systemic embolism in patients (VTE) in adults, including deep venous thrombosis (DVT) and pulmonary embolism (PE), in addition to recurrent VTE prevention (DVT or PE).